FDA-process and commercialization on track. New study results confirm the potential.

Year-End Report (May-January 2018/2019)

SEK thousands	Q4 18/19	Q4 17/18	May-April 18/19	May-April 17/18
Net sales	1,715	1,433	3,005	2,723
Operating profit (loss)	-8,569	-4,132	-21,718	-17,956
Loss for the period	-8,631	-4,176	-21,556	-18,010
Earnings per share, after dilution	-0.47	-0.24	-1.18	-1.01

Significant events during the fourth quarter

- New data from study presented at AACR in April
- Shares now traded on Nasdaq First North Premier
- Lars Holmqvist elected as new Chairman
- Two new customers, a pharmaceutical company and a CRO, and sales of SEK 1.5 million.
- Biovica and IBL America initiate a sales collaboration in USA

Significant events after the end of the period

- Targeted new share issue for SEK 60 million to European and Swedish institutional investors and family offices
- Positive study results with DiviTum® published in the prestigious European Journal of Cancer

CEO's comments

Commercialization of DiviTum® for breast cancer
During the fourth quarter, we achieved several important milestones for launching DiviTum® in the US and European markets.

- In April, we submitted Supplement II to the FDA, detailing our plan for clinical validation
- We presented new, positive results from studies involving 289 patients that confirm the results from prior studies
- We increased sales to the research market and added two major pharmaceutical companies as new customers
- We started off the new financial year with a targeted new share issue, thereby widening the scope of ownership in the company and securing financing for the upcoming commercialization

FDA-process on track
Supplement II, which is in the third stage of the process, was submitted to the FDA in April. It contains a report on Biovica's plan for clinical validation of the product. It is expected that the FDA will provide us with feedback after the summer. As soon as our plan is approved, we can proceed with implementing the actual studies.

Publication of a compilation of all the results from studies
In order to commercialize DiviTum®, our clinical development program must substantiate and document the benefits that DiviTum® can offer to patients and society. Results from studies are required for the regulatory process and for gaining access to the systems that regulate reimbursement to healthcare providers. They are also very important for spreading knowledge of DiviTum®, generating demand and establishing commercial partnerships for sales.

In April, positive results from a study involving 45 patients were presented showing that DiviTum®, as the first blood-based biomarker, can be used to evaluate the effects on patients with metastatic breast cancer who have been treated with palbociclib (CDK4/6 inhibitor).

At the end of May, we published a compilation of all the results from studies where DiviTum® was used in conjunction with breast cancer treatment. It shows the positive results from studies involving more than 1,000 patients where DiviTum® was used in treating breast cancer. The report has been published on Biovica's website and it is important documentation that will be used in discussions with government authorities and commercial partners.

Increased sales to the research market
Sales to the research market increased and amounted to SEK 1.5 million. Customers are major pharmaceutical companies that are using DiviTum® to develop new applications and drugs. The additional revenue boosts the company and confirms the value of DiviTum®. These sales also pave the way for more widespread use of DiviTum®, along with future commercial collaborations.

Broader ownership and equity injection of SEK 60 million
Biovica boosted its equity by SEK 60 million during the fourth quarter via a targeted new share issue. The new share issue was targeted at professional investors like European funds, institutional investors and family offices. In total, 29 professional investors subscribed for shares. The financing provides Biovica with the resources for pursuing its business plan and taking DiviTum® the rest of the way through FDA approval.

Moving closer to the launch of DiviTum®
We're pursuing our commercialization plan, reporting positive results from studies and are involved in a constructive dialog with the FDA on clinical validation of DiviTum®. Biovica has a unique product. It fulfills a great need in a market that is both large and attractive.

I can proudly conclude that we are getting very close to the day when we will launch DiviTum® for clinical use and thereby offer patients with metastatic breast cancer a diagnostic tool ensuring that they get the best possible treatment from day one. In doing so, we will also generate value to our shareholders.

Anders Rylander
CEO

Significant events during the period

DiviTum® is the first biomarker to evaluate the effect of palbociclib in a clinical study that was presented at AACR in Atlanta
New DiviTum® results from a clinical study conducted by Dr Luca Malorni, Prato Hospital, Italy, will be presented at the American Association of Cancer Research (AACR) Annual Meeting in Atlanta, 29 March – 3 April 2019. The study shows that DiviTum® is able to evaluate the effect of palbociclib treatment for women with metastatic breast cancer. The results are unique, in that this is the first biomarker with proven clinical value for this type of targeted therapy.

"This study shows that DiviTum® is able to evaluate the effect of palbociclib treatment for women with metastatic breast cancer. The results are encouraging in terms of the clinical value. With a simple blood sample, we can significantly improve our understanding of when we should use these new drugs and which patients should be selected for treatment so that every patient gets optimal results," says Dr Luca Malorni, Prato Hospital, Italy.

Shares now traded on Nasdaq First North Premier
Biovica started offering its shares for trading on Nasdaq in a new category, First North Premier on 4 March 2019.

Extraordinary general meeting
New Chairman of the Board
Lars Holmqvist was elected as the new Chairman of the Board. Lars brings with him many years of experience and extensive knowledge in the diagnostics field. That, combined with his large international network, is of great value to Biovica as it prepares for commercialization. Lars owns 410,630 B shares in Biovica, directly and via companies. He has also been a member of Biovica's Advisory Board since 2018, so he is well acquainted with the company.

Decision on new warrants scheme
A new warrants scheme consisting of 175,000 warrants offered to the Board of Directors was approved.

Biovica and IBL America initiate a sales collaboration in USA
The agreement with IBL America gives it a non-exclusive right to sell DiviTum® in the research market to pharmaceutical companies, Contract Research Organizations (CRO) and research institutes in the US market. The aim of the collaboration is to increase Biovica's commercial presence and sales in the US research market.

Significant events after the end of the period

Targeted new share issue of SEK 60 million
Via a targeted new share issue that was approved at an extraordinary general meeting on 2 May 2019, Biovica obtained a capital injection of SEK 60 million before issue costs. The price of Biovica's Class B share amounted to SEK 10 and it was established via a book building process. The new share issue resulted in dilution of approximately 25.5 percent on the number of shares and 15.7 percent on the number of votes in Biovica (calculated on the number of outstanding shares after the new issue). The new issue increases the number of outstanding shares by 6,000,000 from 17,573,372 to 23,573,372 and the number of votes increases from 32,168,248 to 38,168,248 (allocated between 7,297,438 Class A shares and 16,275,934 Class B shares). Share capital increased by SEK 400,000.00 (from SEK 1,171,558.13 to SEK 1,571,558.13).

Publication in the European Journal of Cancer
The convincing results that were previously presented from the EFECT study have now been published in the prestigious European Journal of Cancer (impact factor 7.191, which corresponds to the highest 3% in the ranking of scientific journals).

The study evaluated hormonal standard therapy for metastatic breast cancer and DiviTum® was used to evaluate the treatment effect via an ordinary blood sample. DiviTum® was used when analyzing the blood samples of 244 patients and the study documented a distinct correlation between thymidine kinase activity (TKA), a circulating prognostic and monitoring biomarker for patients with metastatic breast cancer treated with hormonal therapy, and the efficacy of the treatment.

Other events

New customers
Two new customers have been added and they've also placed their first orders. Their orders for the DiviTum® kit total approximately SEK 1.5 million. These customers are two global pharmaceutical companies that develop new cancer drugs.

Reclassification of shares
For the fourth time, class A shareholders were offered the opportunity to reclassify their shares to B shares. This occurred on 31 March 2019 and it will be repeated at each quarter-end until the company no longer has any class A shares. A total of 330,000 shares were reclassified.

2019-03-31	Class A shares	Class B shares	Total
Before reclassification	7,627,438	9,945,934	17,573,372
Reclassification	-330,000	330,000	0
After reclassification	**7,297,438**	**10,275,934**	**17,573,372**

AGM

The AGM for the 2018/2019 financial year will be held on 29 August 2019 at 4 p.m. The location is Hubben, Dag Hammarskjölds väg 38 in Uppsala, Sweden. Notice of the AGM will be published on Biovica's website, in Post- och Inrikes Tidningar (gazette) and in SvD (newspaper). The Board of Directors proposes that no dividends shall be distributed to shareholders.

Shareholders who would like to participate in the AGM must be registered in the shareholders' register maintained by Euroclear Sweden AB by Friday 23 August 2019. That is also the deadline for registering intent to participate in the AGM. Notification is by letter to: Biovica International AB, att. Cecilia Driving, Dag Hammarskjölds väg 54B, 752 37 Uppsala, by telephone: +46 (0)18 4444 830 or by email: info@biovica.com.

Company overview

Biovica is a Swedish biotech company with its own laboratory, production facility and head office in Uppsala, Sweden. Biovica has developed DiviTum®, which is an innovative, blood-based biomarker test for measuring the cell proliferation rate of solid tumors. The company is in the early stage of the commercialization process for DiviTum®, where the first application area is evaluation of the treatment effect on metastatic breast cancer.

The vision is for every cancer patient to receive the right treatment from day 1. And this will be possible by using DiviTum® for more personalized treatments. In order to ensure that the product is used in cancer clinics worldwide, Biovica is collaborating with many world-leading oncologists and research groups to prove how valuable the product is in terms of personalized treatments. Results from these collaborations are a key component of generating demand for the product, providing support for its regulatory approval, for reimbursement and for setting up commercial partnerships. Thus far, 16 scientific articles and clinical studies have been published. Biovica has also won several prestigious awards and research grants, including Horizon 2020 (phase 2).

Important partners

The company collaborates with leading partners in healthcare and academia, including Karolinska Institutet (Sweden), Prato Hospital (Italy), Dana Farber Cancer Institute (Boston), Washington University (St Louis), Baylor College of Medicine (Houston), Mayo Clinic (Minnesota), City of Hope Research & Treatment Center (Los Angeles), Johns Hopkins (Baltimore), The International Breast Cancer Study Group (IBCSG) and Breast International Group (BIG).

Technology

DiviTum® is an innovative, blood-based test for measuring the cell proliferation rate of solid tumors. With DiviTum®, the effect of cancer treatment can be measured and tailored from day one, thereby improving the treatment results for patients and generating benefits to society. DiviTum® measures the activity of thymidine kinase (TK) in serum or cells. In normal cells, TK activity is very low. It rises, however, with cell division. Because the level of TK activity is closely associated with cell growth, it has been concluded in many scientific publications that it is a suitable tumor biomarker (Bagegni, 2017 and Bonechi, 2018). Measuring TK activity provides treating physicians with useful information on the tumor cell proliferation rate and aggressiveness.

In the studies it has conducted, Biovica has shown that an assessment of the treatment's effect can be made within 2-4 weeks, while the average time for medical imaging diagnostics is approximately 3-4 months. (Bagegni, 2017 and Bonechi, 2018). And, all that's required for analysis with DiviTum® is a simple blood sample. By quickly and reliably being able to determine if a drug is having any effect, treatment can thereby be tailored and optimized.

Breast cancer

Each year, approximately 8,000 Swedish women are diagnosed with breast cancer. Approximately 1 out of every 10 women will develop breast cancer and prevalence of the disease has increased over the last twenty years. Four out of five women diagnosed with breast cancer are over 50 years old. There are various stages of cancer. For example, Stage I means that cancer is small and only in one area. Stage IV, however, means that the cancer has spread to other parts of the body. When breast cancer is discovered early, the prognosis is good. In such cases, four out of every five women are still alive five years after having been diagnosed with cancer. In the EU and USA, there are approximately 450,000 women with metastatic breast cancer. Recently, research has made advancements in the

area of recurrent/metastatic breast cancer. Women with metastatic breast cancer can be offered a variety of new treatments to slow progression of the disease and reduce the size of tumors. But, some patients respond well to certain treatments, others less so. This is why it is important to have tools for selecting the right treatment for each person and quickly evaluate whether it is having any effect. With medical imaging diagnostics, 3-4 months is typically required to analyze volume changes. DiviTum® has been developed to provide information on treatment within 2-4 weeks. All that is required is a simple blood sample. It can also help doctors determine whether the patient is on the right treatment, and, if not, switch to a more effective one.

For metastatic breast cancer, the market potential for DiviTum® in USA and the EU is estimated at approximately SEK 6 billion.

Patent protection

Biovica owns two patent families. Patent protection on the company's ELISA assay technique expires in 2026. Patent protection on the company's real-time method of measuring TK activity expires in 2031. It was added to Biovica's product portfolio in conjunction with its acquisition of cSens in 2016. The acquisition increased the scope of Biovica's patent portfolio. It also extended patent protection for Biovica's portfolio by 5 years in the company's main markets.

Overview of concluded and ongoing studies on breast cancer.



Ongoing studies

DiviTum® is repeatedly mentioned and documented in many international and national studies on metastatic breast cancer, which is Biovica's first commercial application. Biovica has 8 ongoing clinical breast cancer studies. The company is also involved in an ongoing study on lung and gastrointestinal cancer.

At SABCS 2017, a study by Lund University was presented. It involved 142 patients with metastatic breast cancer and its purpose was to measure the treatment effect of 3 types of standard treatment.

At AACR 2019, the results of DiviTum® from the TREnd study will be presented. The study shows that DiviTum® is able to evaluate the effect of palbociclib treatment for 45 patients with metastatic breast cancer.

Together with Johns Hopkins, Biovica is conducting a study involving 100 patients to measure drug resistance development, including CDK 4/6 inhibitor.

PYTHIA is a study that is being conducted by BIG and IBCSG involving 120 stage IV patients to measure the treatment effect of targeted therapy.

Together with University of Pennsylvania, Biovica is conducting a pilot study involving 28 stage IV patients to measure the effect of combination treatment with chemotherapy and targeted therapy.

FELINE is a study that is being conducted by University of Kansas involving 120 stage III patients aimed at measuring the effect of targeted therapy and correlation with other biomarkers.

Together with City of Hope, Biovica is conducting a pilot study involving 18 patients to measure the effect of two new cancer drugs.

PREDIX is a study that is being conducted by Karolinska Institutet involving 200 stage III patients to measure the effect of targeted therapy and the survival rate.

Biovica has also started collaborating with WntResearch to identify patients with colon cancer who could benefit from Foxy-5 treatment. A Phase II study will be conducted with these patients to investigate the potential of using DiviTum® to supplement Foxy-5 and potentially become a Companion Diagnostic (CDx) to the drug.

Summary of published studies on breast cancer

Thus far, six studies have been published in scientific journals where DiviTum® was used for evaluation of breast cancer treatment.

Biovica collaborates globally with leading cancer researchers, medical institutes and pharmaceutical companies to provide strong pre-clinical and clinical evidence of the effectiveness of DiviTum®. Studies have been conducted with more than 1,000 patients (early-stage to metastatic breast cancer) where DiviTum® has successfully been used to assess TK activity as a suitable biomarker for measuring tumor growth and as a monitoring tool for treatment response. The studies have shown that DiviTum® is a successful prognostic tool for patient survival, as well as a monitoring tool for obtaining early evidence of treatment response with endocrine therapy, and cyclin-dependent kinase (CDK) inhibitors.

The use of DiviTum® as a quick and precise monitoring and prognostic tool has been substantiated by a vast amount of evidence that has been collected from carefully designed, randomized, controlled trials. Thus far, DiviTum® has been used in 8 studies involving more than 1,000 patients with early stage cancer (n = 211) and metastatic breast cancer (n = 845) in collaboration with world-leading oncologists and medical institutes in several countries including Israel, Sweden, Italy, USA and China. DiviTum® has been studied:

- prospectively in two major studies as a prognostic factor for PFS (progression-free survival) and OS (overall survival) of more than 400 patients with metastatic breast cancer;
- as a monitoring tool for obtaining early evidence of treatment response with endocrine therapy in two studies involving more than 270 patients with metastatic breast cancer;
- to evaluate the effects on patients with early stage breast cancer (in a study involving more than 50 patients) who have been treated with CDK inhibitors; and
- in two studies involving 140 patients with metastatic breast cancer.

In addition to the positive results from studies using DiviTum® to treat breast cancer, many studies have been conducted where DiviTum® has been used in the treatment of lung, liver, pancreatic and colorectal cancer substantiating the effectiveness of DiviTum® as a prognostic tool for measuring and monitoring the effect of treatment over time.

Clinical studies have shown that DiviTum® is particularly useful as a prognostic tool for tumor cell proliferation rate and aggressiveness, as well as the overall survival in patients with stage III-IV breast cancer. Its potential has also been substantiated as a monitoring tool for obtaining early evidence of treatment response and resistance to chemotherapy, endocrine therapy and CDK inhibitors such as palbociclib.

DiviTum® has been used to evaluate the treatment effect of standard hormonal therapies on patients with metastatic breast cancer via an ordinary blood sample. (McCartney, 2019)

DiviTum® both predicts and shows the effect of endocrine treatment for metastatic breast cancer. (Bonechi, 2018)

The effect of CDK4/6 inhibitor treatment is reflected in changes in TK activity for stage II/III patients with breast cancer. (Bagegni, 2017)

DiviTum® predicts PFS (progression free survival) and OS (overall survival) for patients with metastatic breast cancer. (Bjöhle, 2013)

DiviTum® is able to predict the risk of recurrence within five years of surgery for patients with breast cancer. (Nisman, 2010)

DiviTum® predicts the risk of developing breast cancer in women with BRCA1 and BRCA2 mutations. (Nisman, 2013)

Glossary and explanations

PFS progression free survival – the length of time during and after the treatment that a patient lives with the disease but it does not get worse

OS overall survival

SABCS San Antonio Breast Cancer Symposium is held each year in December. It is the world's largest breast cancer symposium.

AACR American Association for Cancer Research – the world's largest conference focused on cancer research. It is held each year, in April.

ASCO American Society of Clinical Oncology – the world's larges cancer congress with clinical focus. It is held each year in June.

Scientific articles

Breast cancer
McCartney A, et al. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). European Journal of Cancer 2019; 114: 55-66

Bonechi M et al. Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget 2018; Mar; 9 (23): 16389-16399.

Bagegni N, et al. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Res and Treat. 2017; Nov 21;19(1):123.

Bjöhle J, et al. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res and Treat 2013; 139(3):751-8.

Nisman B, et al. Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2013; Nov; 22(11):2110-5.

Nisman B, et al. Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark. 2010; 7(2):65-72.

Lung cancer
Nisman B, et al. Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients. J Thorac Oncol 2014; Oct; 9(10):1568-1572.

Korkmaz T, et al. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer. Biomarkers 2013; Feb;18(1):88-94.

Pancreatic cancer
Felix K, et al. Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer. Pancreas. 2017; Nov 16.

Breast cancer and colorectal cancer
Bolayirli M, et al. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy. J Clin Lab Anal. 2013; May;27(3):220-6.

Kidney cancer
Nisman B, et al. Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver. Anticancer Res. 2016; Apr;36(4):1791-7.

Nisman B, et al. Circulating Tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nefrectomy. Urology; 76 (2), 513. e1-e6, 2010.

Blood cancer
Stelmach P, et al. Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia. Postepy Hig Med Dosw. 2016; 70(0):1321-1330.

Bacovsky J, et al. Analysis of thymidine kinase serum levels by novel method DiviTum™ in multiple myeloma and monoclonal gammopathy of undetermined significance – comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CT. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015; Mar;159(1):135-8.

Procházka V, et al. High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. Leuk Lymphoma 2012; Jul;53(7):1306-10.

Rivkina A, et al. Identifying the stage of new CLL patients using TK, ZAP-70, CD38 levels. Exp. Oncology 2011; 33(2), 99-103.

Method
Nisman B, et al. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients. Clin Chem Lab Med. 2013; 51(2):439-47.

Comments on the financial performance of the Group

Q4 - Sales and earnings

Net sales for the period amounted to SEK 1,751 (1,433) thousand.

Capitalized work performed by the company for its own use amounts to SEK 1,515 (1,647) thousand. The capitalized amount pertains to expenditure to further develop DiviTum® for measuring thymidine kinase (TK).

Operating expenses amount to SEK -12,349 (-7,412) thousand.

The operating loss for the period was SEK -8,569 (-4,132) thousand.

Net financial items amounted to SEK -26 (-45) thousand. Loss after financial items was SEK -8,596 (-4,176) thousand. Profit or loss for the period was SEK -8,631 (-4,176) thousand.

As of 30 April 2019, the company had 17 (14) employees, of which 9 (8) are women.

Full year 2018/2019 - Sales and earnings

Net sales for the period amounted to SEK 3,005 (2,723) thousand, which is approximately a 10 percent increase compared to last year.

Capitalized work performed by the company for its own use amounts to SEK 6,464 (6,596) thousand. The capitalized amount pertains to expenditure to further develop DiviTum® for measuring thymidine kinase (TK).

Operating expenses amount to SEK -32,162 (-27,901) thousand. Operating expenses increased during the period, which is attributable to the high level of activity in several projects, such as a comprehensive market analysis that was conducted.

The operating loss for the period was SEK -21,718 (-17,956) thousand.

Net financial items amounted to SEK -194 (-54) thousand. Loss after financial items was SEK -21,524 (-18,010) thousand. Profit or loss for the period was SEK -21,556 (-18,010) thousand.

As of 30 April 2019, the company had 17 (14) employees, of which 9 (8) are women.

Financial position, cash flow and investments

The closing amount for cash & cash equivalents on 30 April 2019 was SEK 16,831 (42,127) thousand. Subsequent to year-end, Biovica received a capital injection of SEK 60 million, which will cover its operations for more than 12 months.

The year's capitalized expenditure for development work is SEK 6,464 (6,596) thousand.

Investments in property, plant and equipment in the form of equipment for the year is SEK 969 (1,989) thousand.

Warrants

Biovica has four warrant schemes. The warrant scheme decided on 27 January 2014 (TO1) is for members of the Board of Directors. The scope is 13,000 warrants (which, after a 1:15 split entitled each warrant holder to subscribe for 15 new class B shares) at a subscription price of SEK 16.7 per share during the period 7 July 2014 – 30 June 2019. Each warrant required payment of SEK 0.68. With full subscription of the issued warrants, Biovica can increase its share capital by, at most, approximately SEK 13,650 and the number of shares by, at most, 195,000.

For the warrant scheme decided at the extraordinary general meeting on 24 January 2017 (TO2), warrants were offered to all Biovica employees for SEK 0.54/warrant based the Black-Scholes pricing model for determining the fair market value. Each warrant entitles the holder to subscribe for one new class B share at SEK 25 per share during the period 29 March 2017 through 30 March 2020. With full subscription of the issued warrants, Biovica can increase its share capital by, at most, approximately SEK 13,333.33 and the number of shares by, at most, 200,000.

At the AGM on 30 August 2018, it was decided to set up an additional warrant scheme for employees (TO3). The warrants have been valued at SEK 0.44. Each warrant entitles the holder to subscribe for one new class B share at SEK 21.9 per share during the period 30 August 2020 through 25 August 2021. With full subscription of the issued warrants, Biovica can increase its share capital by, at most, approximately SEK 13,333.33 and the number of shares by, at most, 200,000.

At the extraordinary general meeting on 20 March 2019, it was decided to set up a warrant scheme for members of the Board of Directors (TO4). The warrants will be valued in accordance with the Black-Scholes pricing model. Each warrant entitles the holder to subscribe for one new class B share at a per share price corresponding to 200 percent of the volume-weighted average price for class B shares on traded on Nasdaq First North during the ten (10) trading days prior to the extraordinary general meeting that was held on 20 March 2019. Holders may subscribe during the period 25 August 2022 through 25 August 2023. With full subscription of the issued warrants, Biovica can increase its share capital by, at most, approximately SEK 11,666.67 and the number of shares by, at most, 175,000.

Related party transactions

During the year, the company, represented by parties related to the main owner and board member, Anders Rylander, leased office facilities to the Parent Company. The total fee for rent paid was SEK 194 thousand. Transactions were in accordance with market-based terms and conditions.

Policies for preparing the interim report

Accounting policies
The Group applies the Annual Accounts Act, International Financial Reporting Standards (IFRS) that have been adopted by the EU and RFR 1 Additional Accounting Regulations for Groups when preparing the financial statements. The Parent Company applies RFR 2 Accounting for Legal Entities when preparing the financial statements. The applied accounting policies otherwise correspond with those described in the Annual Report for 2017/2018. This interim report was prepared in accordance with IAS 34, Interim Financial Reporting.

IFRS 15
IFRS 15 entered into force on 1 May 2018. It will not have any impact on the financial statements. Revenue that has been recognized in this report results from the sale of goods and it has been recognized as goods transferred at a specific time. Only one product was sold during the period. Essentially all sales were to the US market.

Seasonal fluctuations
There are no seasonal fluctuations associated with sales.

IFRS 9
The Group has not identified any impact on the classification and measurement of its financial assets and liabilities. IFRS 9 entered into force on 1 May 2018.

NEW IFRS AND INTREPRETATIONS THAT HAVE NOT YET BEEN APPLIED, IFRS 16 LEASES
IFRS 16 Leases replaces IAS 17 Leases as of 1 May 2019. For Biovica, as lessee, the application of IFRS 16 means that essentially all leases will be reported in the balance sheet as assets (its right to use the underlying leased asset) and liabilities (the obligation to make future lease payments). Biovica must also recognize depreciation of the right-of-use asset and interest on the lease liability in the income statement. The impact on earnings before tax is assessed as being insignificant. New lease agreements are for the office space and premises.

For transition to the new standard, Biovica has decided to apply the modified retroactive approach and option two, where the right-of-use asset equals the liability upon transition, subject to certain adjustments (any prepaid or accrued lease payments). Election of this method also means that comparison periods are not restated.

Lease agreements shorter than 12 months, or which terminate within 12 months of the transition date are classified as short-term agreements. As such, they are not included in the liabilities or ROU assets. Furthermore, Biovica has elected to apply the recognition exemptions to leases for which the underlying asset is of low value.

Existing lease agreements previously reported in accordance with IAS 17 Lease have been reclassified in accordance with IFRS 16 Leases at the amount at which they were reported the day before application of the new standard.

A marginal lending rate has been established for each country, useful life and asset class.

The effects of the transition to IFRS 16 are detailed below.

SEK 000s	**Adjustment 1: May 2019**
PPE, right-of-use	3,618
Lease liabilities, interest-bearing	3,618

PARENT COMPANY
IFRS 15 Revenue from Contracts with Customers has not had any impact on the Parent Company's recognition of revenue. IFRS 9 Financial Instruments requires implementation of new rules for recognition of impairment based on expected credit losses. The Parent Company's current receivables from Group Companies fall within the

scope of the impairment rules stipulated in IFRS 9. These receivables primarily consist of Group contributions that will be settled soon after the closing date. Based on materiality, no provision is made for expected credit losses on these claims. Beyond that, IFRS 9 has not had any impact on the financial statements as of 1 May 2018. The new standard, IFRS 16 Leases, which enters into force as of 1 January 2019, has no effect on the Parent Company since the standard is exempt from application by legal entities and the Parent Company only uses leasing to a limited extent.

Significant risks and uncertainties

There are several risks and uncertainties associated with the company's operations. For a more detailed description of the risks (in Swedish), please see the Annual Report for 2017/2018. The risks have not changed compared to what is described in the Annual Report.

KPIs for the Group

SEK thousands	Full year 18/19	Full year 17/18	Full year 16/17	Full year 15/16
Net sales	3,005	2,723	632	2,432
Operating profit (loss)	-21,718	-17,956	-14,690	-4,617
Net profit (loss) for the year	-21,556	-18,010	-14,715	-5,049
Capitalized R&D expenditure	6,464	6,596	5,075	4,700
Capitalized R&D exp., % of op. expenses	-22	-26	-27	-37
Earnings per share, basic	-1.23	-1.02	-0.84	-0.54
Earnings per share, after dilution	-1.18	-1.00	-0.82	-0.53
Cash and cash equivalents at the end of the period	16,831	42,127	65,469	928
Cash flow from operating activities	-17,966	-14,882	-10,746	-9,385
Cash flow for the period	-25,295	-23,342	64,541	-179
Equity	52,097	73,713	91,664	24,881
Equity per share	2.96	4.19	5.22	44.51
Equity ratio (%)	86	91	94	88
Average number of employees	16	14	8	5

Definitions are the same as those presented in the Annual Report for 2017/2018.

Financial information

Consolidated income statement and summary statement of comprehensive income

SEK thousands	Q4 18/19	Q4 17/18	May-April 18/19	May-April 17/18
Net sales	1,715	1,433	3,005	2,723
Other income	609	171	932	494
Work performed by the company and capitalized	1,515	1,647	6,464	6,596
Change in WIP inventory	-60	29	43	132
	3,779	**3,280**	**10,444**	**9,945**
Materials cost	-153	-426	-875	-1,148
Other external costs	-5,615	-2,480	-11,962	-9,503
Employee benefit expenses	-5,556	-3,806	-16,245	-14,495
Depreciation/amortization	-965	-683	-3,020	-2,738
Other expenses	-60	-17	-60	-17
Operating profit (loss)	**-8,569**	**-4,132**	**-21,718**	**-17,956**
Other interest income and similar profit or loss items	0	0	229	0
Interest expenses and similar items	-26	-45	-35	-54
Loss after financial items	**-8,596**	**-4,176**	**-21,524**	**-18,010**
Tax expense	-35	0	-32	-
Net profit (loss) for the year	**-8,631**	**-4,176**	**-21,556**	**-18,010**
Consolidated statement of comprehensive income				
Net profit (loss) for the year	-8,631	-4,176	-21,556	-18,010
Exchange diff. foreign net invest.	0	0	0	0
Other comprehensive income for the year	0	0	0	0
Comprehensive income for the year (loss)	**-8,631**	**-4,176**	**-21,556**	**-18,010**
Earnings per share				
Earnings per share, before dilution (SEK)	-0.49	-0.24	-1.23	-1.02
Average number of shares, before dilution	17,573,372	17,573,372	17,573,372	17,573,372
Earnings per share, after dilution (SEK)	-0.47	-0.24	-1.18	-1.01
Average number of shares, after dilution	18,343,372	17,968,332	18,343,372	17,968,332

Consolidated statement of financial position, in summary

SEK thousands	2019-04-30	2018-04-30
ASSETS		
Intangible assets	37,907	33,778
Property, plant and equipment	2,917	2,616
Financial assets	0	0
Total fixed assets	**40,825**	**36,394**
Inventories	446	403
Accounts receivable	1,732	1,068
Current receivables	1,026	779
Cash and bank	16,831	42,127
Total current assets	**20,035**	**44,377**
TOTAL ASSETS	**60,859**	**80,771**
EQUITY		
Share capital	1,172	1,172
Other contributed capital	133,776	133,776
Retained earnings (losses), including net loss for the year	-82,850	-61,235
Total equity	**52,097**	**73,713**
Other non-current liabilities	940	387
Advance payments from customers	3,571	3,047
Accounts payable	860	1,009
Current tax liabilities	557	16
Other liabilities	545	482
Accrued expenses and deferred income	2,289	2,117
Current liabilities	**7,822**	**6,672**
TOTAL EQUITY AND LIABILITIES	**60,859**	**80,771**

Consolidated statement of changes in equity, in summary

SEK thousands	Share capital	Other contributed capital	Retained earnings (losses)	Net profit (loss) for the year	Total equity
Opening balance, 1 May 2017	**1,172**	**133,776**	**-28,569**	**-14,715**	**91,664**
Appropriation in accordance AGM decision			-14,715	14,715	–
Adjustment			59		59
Net profit (loss) for the year				-18,010	-18,010
Opening balance, 1 May 2018	**1,172**	**133,776**	**-43,225**	**-18,010**	**73,713**
Appropriation in accordance AGM decision					–
Adjustment			-59		-59
Translation difference					–
Net profit (loss) for the year				-21,556	-21,556
Closing balance, 30 April 2019	**1,172**	**133,776**	**-61,294**	**-21,556**	**52,097**



Consolidated statement of cash flows, in summary

SEK thousands	Q4 18/19	Q4 17/18	May-April 18/19	May-April 17/18
Cash flow from operating activities before changes in working capital	-4,522	-3,526	-17,788	-15,009
Changes in working capital	-421	18	-179	127
Cash flow from operating activities	**-4,942**	**-3,509**	**-17,967**	**-14,882**
Cash flow from investing activities	-2,430	-1,721	-7,329	-8,459
Cash flow from financing activities	–	–	0	0
Cash flow for the period	**-7,372**	**-5,230**	**-25,296**	**-23,342**
Cash and cash equivalents at the beginning of the period	24,203	47,357	42,127	65,469
Cash and cash equivalents at the end of the period	16,831	42,127	16,831	42,127

Parent Company income statement, in summary

SEK thousands	Q4 2018/2019	Q4 2018/2017	Full year 2018/2019	Full year 2017/2018
Net sales	1,736	1,433	3,005	2,723
Change in WIP inventory	149	29	751	132
Work performed by the company and capitalized	1,899	1,647	6,464	6,596
Other operating income	-58	171	43	494
Sales	*3,727*	*3,280*	*10,263*	*9,945*
Goods for resale	-238	-426	-875	-1,148
Other external costs	-4,884	-2,539	-12,638	-9,595
Employee benefit expenses	-4,318	-3,806	-15,736	-14,495
Depreciation/amortization	-711	-120	-2,840	-2,584
Other operating expenses	-38	-17	-60	-17
Operating expenses	*-10,189*	*-6,908*	*-32,149*	*-27,839*
Operating profit (loss)	**-6,462**	**-3,628**	**-21,886**	**-17,894**
Net financial income/expense	508	-42	280	-42
Loss after financial items	**-5,954**	**-3,669**	**-21,606**	**-17,935**
Income tax	0	0	0	0
Loss for the period	**-5,954**	**-3,669**	**-21,606**	**-17,935**
Earnings per share				
Earnings per share, before dilution (SEK)	-0.34	-0.21	-1.23	-1.02
Average number of shares, before dilution	17,573,372	17,573,372	17,573,372	17,573,372
Earnings per share, after dilution (SEK)	-0.33	-0.20	-1.19	-1.00
Average number of shares, after dilution	18,143,372	17,968,372	18,143,372	17,968,372

Comprehensive income (loss) equals the loss for the period.

Parent Company balance sheet, in summary

SEK thousands	2019-04-30	2018-04-30
ASSETS		
Intangible assets	37,907	33,719
Machinery and equipment	1,801	2,191
Financial assets	300	147
TOTAL FIXED ASSETS	*40,008*	*36,057*
Inventories	446	403
Current receivables	3,738	1,847
Cash and bank	15,779	42,069
TOTAL CURRENT ASSETS	*19,963*	*44,319*
TOTAL ASSETS	**59,972**	**80,376**
EQUITY AND LIABILITIES		
Total restricted equity	19,307	12,842
Total non-restricted equity	32,699	60,769
TOTAL EQUITY	*52,005*	*73,611*
Total non-current liabilities	0	109
Total current liabilities	7,966	6,655
TOTAL LIABILITIES	*7,966*	*6,764*
TOTAL EQUITY AND LIABILITIES	**59,972**	**80,376**

Uppsala, 14 June 2019

Board of Directors

This report has not been reviewed by the company's auditor.

Calendar

Annual Report 24-30 June, 2019	
AGM	29 August 2019
Interim Report for Q1: May-July 2019	29 August 2019
Interim Report for Q2: August-October 2019	5 December 2019
Interim Report for Q3: November - January 2020	12 March 2020
Interim Report for Q4: February – April 2020	12 June 2020

Conference call/Audiocast, in English, on 14 June 2019 at 10.00 CET.

https://tv.streamfabriken.com/biovica-international-q4-2018

SE: +46850558355, DK: +4578150109, UK: +443333009274, US: +18335268381

For more information, please contact:

Anders Rylander, CEO
Phone: +46 (0)18-44 44 835
Email: anders.rylander@biovica.com

Cecilia Driving, CFO
Phone +46 (0)73 125 92 47
Email: cecilia.driving@biovica.com

Biovica International AB (publ), 556774-6150
Dag Hammarskjölds väg 54B
752 37 Uppsala
+46 (0)18-44 44 830

About Biovica
Biovica develops and commercializes blood-based biomarker assays for evaluating the effect of cancer treatments. Biovica's DiviTum® technology measures cell proliferation rate and clinical studies have shown that it can quickly reveal whether treatment is effective. Biovica's vision is a future where every patient receives the best possible therapy from the very first day of treatment. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies to develop next-generation cancer therapies. Biovica has obtained ISO 13485 certification DiviTum® has CE marking and it is registered with the Swedish Medical Products Agency. Biovica's class B shares are listed on Nasdaq First North. FNCA Sweden AB is the appointed Certified Adviser.

For more information, please visit the company's website: www.biovica.com